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Background: The trial protocol is the most important document for clinical trials and describes not only the design
and methodology of a study, but also all practical aspects. The suitability of the protocol has a direct impact on the
execution and results of the trial. However, suitability is rarely addressed in trial practice and research. The aim
of our study was to investigate protocol suitability and to identify suitability-enhancing measures for trials in
sub-Saharan Africa.
Methods: We used an exploratory mixed methods design. First, we interviewed 36 trial staff at different organisational
levels in Ghana, Burkina Faso and Senegal. Second, we conducted an online survey among trial staff in sub-Saharan
Africa to investigate trial protocol suitability based on the main themes distilled from the interviews.
Results: Protocol suitability surfaced as a prominent topic in interviews with trial staff, critiqued for its lack of clarity,
implementability and adaptation to trial participants as well as to the workforce and infrastructure available. Both
qualitative and quantitative investigations identified local site staff involvement in protocol development as the
most helpful mean of increasing protocol suitability. Careful assessment of the local context, capacity and cultures,
and ensuring that staff understand the protocol were also cited as helpful measures.
Conclusions: Our data suggests that protocol suitability can be increased by discussing and reviewing the protocol
with trial staff in advance. Involving operationally experienced staff would be most useful. For multicentre trials, we
suggest that at least one trial staff member from each of the sites with the highest expected recruitment rates be
involved in developing the protocol. Carefully assessing the context prior to study start is indispensable to ensuring
protocol suitability and should particularly focus on the workforce and infrastructure available, as well as the needs
and availability of trial participants. To allow for protocol suitability enhancing measures, planners must allocate
enough time for trial preparation and solicit feedback and information on context at an early stage. Such prospective
planning would increase implementability, efficiency and quality of trials in the long run.Background
Clinical trials are essential for developing new medicines
and for improving disease management. From a public
health perspective, clinical trials in sub-Saharan Africa
(SSA), where high burdens of disease exist, are of par-
ticular importance. Trials conducted in this region face
particular setting-specific challenges like deficits in in-
frastructure and skilled workforce, in addition to the* Correspondence: Nerina.vischer@unibas.ch
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itional challenges derive from the difficulties of getting
patient information and consent [1] and the frequent
involvement of children.
The most important document in a clinical trial is the
trial protocol, the key document for planning, conducting,
externally reviewing, overseeing and interpreting a study
[2]. The trial protocol provides a rational for the trial,
defines trial goals, processes and analysis methods and
enables scientific and ethical review. A well-designed
protocol is paramount for a successful clinical trial for
several reasons. First, the study design described in the
protocol significantly affects the costs of conductingle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
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amendments [2] and protocol deviations, which trigger
queries and add to already heavy workloads. Protocol
amendments are costly [4], may jeopardize data integ-
rity [5] and trial participants’ safety, and cause delays
and disruptions of the trial [4]. One study found that
nearly half of all amendments may be avoidable [6].
Third, the length and complexity of protocols have in-
creased dramatically over the past decades. Higher
protocol complexity is directly associated with a greater
number of amendments, lower levels of study perform-
ance [3, 7] and increases chances of non-adherence
and, hence, of risk and low quality. The frequency of
procedures per protocol has also increased at an annual
rate of 8.7%, which adds to on-site work burdens [8].
The number of protocol deviations is one of the key
measures for trial quality [9] and protocols are the most
important instrument for quality risk management. In
summary, the protocol largely determines quality, out-
comes, efficiency and potential challenges in clinical tri-
als. Getz et al. state that protocol design may hold the
key to achieving higher levels of efficiency [8]. Despite
the challenges mentioned above and the apparent im-
portance of the protocol, there is little research on how
to optimize the conduct of trials in the North as well as
in resource-limited countries [10, 11]. Gheorghiade
et al. criticise the limited data available to support best
trial practices and that we only rely on experience and
judgment [12].
To standardise the content and ensure the quality of
trial protocols, the ICH E6 guideline “Good Clinical
Practice” contains a full chapter on trial protocols [13].
The SPIRIT 2013 Statement (Standard Protocol Items:
Recommendations for Interventional Trials) is a more
comprehensive checklist of recommended items to in-
clude in a trial protocol [2]. This checklist was devel-
oped based on the argument that high-quality protocols
facilitate proper conduct, reporting and external review
of clinical trials, and that the completeness of trial proto-
cols was often inadequate. In addition, the World Health
Organisation’s website offers instructions for designing
and formatting a research protocol [14]. TransCelerate
Biopharma Inc. developed the freely available “Common
Protocol Template” to improve consistency across the in-
creasingly complex protocols [15]. Other free protocol
templates are available on the web [16, 17]; selecting the
correct template depends on local laws, regulations and
the sponsor. All efforts described above mainly focus on
the scientific part of the protocol, which is of most interest
to researchers and reflects their training.
However, a trial protocol goes beyond describing the
research design. It also serves as an operational manual
and must satisfy experts from different backgrounds and
disciplines [18]. To date, little emphasis has been placedon protocol operationalization. Getz and Campo state
that protocol authors often transfer out-dated and un-
necessary procedures into next study designs because they
are routinely carried over from long-standing protocol
templates and operating policies [7].
A key aspect of operationalization is protocol feasibil-
ity, which is customarily assessed after the protocol has
been finalised by the sponsor. It is currently common
practice in clinical trials to have a site feasibility assess-
ment and/or a pre-study visit. During both visits, facil-
ities are commonly assessed using a standard template
in a checklist format that is often used across studies
and is not tailored to the specific operational require-
ments of the trial protocol. On the global health trials
webpage, such a protocol feasibility checklist is freely
available [19]. To the best of our knowledge, there is
only one study covering this topic [3]. This study high-
lights that protocol design feasibility is a topic of increas-
ing interest to sponsor organizations and recommends
more flexible and adaptive trial designs as well as more
rigorous upfront planning and simulation.
In contrast to “feasible”, which is defined as achievable
and possible, “suitable” is defined as fit for purpose [20].
Protocol suitability goes beyond feasibility and addresses
not only technical aspects of the protocol but also con-
siders settings, environments and culture, as well as effect-
iveness and efficiency of execution. These are of particular
importance, as the protocol serves as a manual for health
care providers [18]. Protocols that cannot be effectively
executed may result in protocol deviations, amendments,
quality issues and safety problems. While feasibility of trial
sites is routinely assessed, protocol suitability is a new
concept and rarely considered. Meeker-O’Connell et al.
stress that improving protocol design, trial planning and
quality oversight has a direct impact on inefficiencies like
high costs and unsustainability [21]. With the rising com-
plexity of trial protocols and the intense pressure on spon-
sors to accelerate development cycle times, suitability is
becoming more important to alleviate execution burdens
and ultimately improve trial conduct efficiency [8].
The study presented here covers protocol suitability
for clinical trials in SSA that investigate poverty-related
diseases. Ensuring protocol suitability is particularly dif-
ficult in these regions due to the geographical separation
between sponsors and trial teams. To the best of our
knowledge, this is the first study investigating trial
protocol suitability in SSA. As clinical research is more
established in South Africa and not exactly comparable
with other SSA-countries, we excluded South Africa
from our study [22].
Clinical trial staff in SSA implement the trial protocols
in practice and can provide valuable insights regarding
protocol suitability. Nevertheless, the experience of trial
staff is rarely acknowledged in scientific publications.
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on trial protocols using qualitative methods could shed
light on the factors that facilitate the conduct of clinical
research [23]. Hence, we assessed trial staffs’ perspec-
tives by using an exploratory mixed methods approach,
combining qualitative and quantitative methods. Mixing
two methods has the capacity to strengthen results and
conclusions [24]. The aim of our study was to identify




We used an exploratory mixed methods design, which is
an ideal approach to exploring a topic for which no re-
search has been carried out so far [24]. We started with
a qualitative part, conducting key informant interviews
with clinical trial staff working in SSA, to identify im-
portant variables of protocol suitability. In order to
quantify identified variables, increase generalizability
and explore correlations between variables, we followed
up with a quantitative part comprising an online survey
targeting trial staff. We used the connection approach,
deriving major themes from the qualitative interviews
and using them to develop and formulate the questions
and answer options in the quantitative survey [25].
Ethical review exemption for the whole project was
granted by the Ethics Committee of North-Western and
Central Switzerland (EKNZ), based on the rationale that
the research project did not involve access to or collect
private, sensitive or health-related data or materials. For
the qualitative study, we received full ethical clearance
from the Ghana Health Service Ethical Review Committee
(GHS-ERC: 18/09/14), the Comité d’Éthique sur la
Recherche en Santé in Burkina Faso (N 2014-11-131)
and the Comité National d’Éthique pour la Recherche
en Santé in Senegal (n12/MSAS/DPRS/CNERS).
Qualitative methods
We visited clinical research centres in Ghana, Burkina
Faso and Senegal as they significantly contribute to public
health activities in SSA and because the Swiss Tropical
and Public Health Institute (Swiss TPH) has contacts with
clinical research centres in these countries. In all three
countries, we contacted the major clinical research centres
that focus on poverty-related diseases and have a track
record of completed clinical trials (no more than four such
centres could be identified per country). In every country,
we selected the first two research centres that agreed to
our visit and ultimately conducted interviews in six cen-
tres, four of which were located in an urban setting and
two in a rural setting. To ensure anonymity of inter-
viewees, neither the names nor the exact locations of the
clinical research centres are mentioned here. Interviewswere open to all centre investigators, study coordina-
tors, clinicians and quality assurance professionals with
at least six months of experience in clinical research. In
each centre, the sample was drawn with the assistance
of a clinical researcher working in the centre, who
approached eligible participants and acquainted them
with this study.
Building on the literature and through pre-test with
trial personnel working in SSA, we finalized the inter-
view guide in an interdisciplinary team. Among other as-
pects, the guide consisted of the following questions:
– In your experience what is important for a good
study protocol that is easy to implement?
– Could trial protocols be improved? If yes how and
where?
– What is the influence of the study protocol on the
trial?
– Who is writing the protocols you are working with?
All interviews were conducted by the first author of
this paper. In Ghana, key informant interviews were
conducted in English in December 2014. After translat-
ing the interview guide into French (including back-
translation and terminology review), we conducted in-
terviews in Burkina Faso and Senegal in March and
April 2015. In each country, we considered having
reached saturation of information in the number of in-
terviews conducted when few or no new concepts were
raised [26]. Unstructured observations, reflections dur-
ing interviews and informal conversations with external
monitors (who were on-site during our visit) were col-
lected and documented in a field diary.
After explaining the purpose of the study and inform-
ing the participants of their right to withdraw from the
study at any given time, participants gave written con-
sent. Interviews were tape-recorded, transcribed verba-
tim and analysed using thematic analysis as per Braun
and Clarke [27]. After repeated reading of the tran-
scripts, initial coding was performed in MAXQDA 11.
The analysis focused on the suitability of trial protocols.
To ensure the analysis was reflective, notes were taken.
We tested emerging themes from the data interrogation
in further interview analyses. Themes were cross-
tabulated to explore differences between countries and
staff levels before finally defining and naming themes.
This study adhered to consolidated criteria for reporting
qualitative research (COREQ) [28].
Quantitative methods
The survey was based on the key themes that emerged
from the qualitative interviews, namely protocol charac-
teristics, context adaptation and involvement of site staff.
We developed the survey in a team that included clinical
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discussed it with and received input from the European
& Developing Countries Clinical Trials Partnership
(EDCTP), a funder of investigator-initiated trials and ac-
tive in SSA since 2003. The resulting survey (Additional
files 1 and 2) consisted of single and multiple selection
questions and ranking of table lists related to the follow-
ing topics: protocol characteristics, adaptation of proce-
dures and practical aspects in the protocol, measures to
increase protocol suitability, and current and most help-
ful involvement in protocol development. The survey
also captured the experience of participants and the de-
gree to which measures were implemented. The survey
was deployed using a web-based survey tool developed
for researchers at the University of Basel (FlexiForm©).
The survey was piloted among 12 participants who
had varying positions in the field of clinical research in
SSA. As the relevance of the questions had already been
tested in the qualitative interviews, the pilot run focused
on the comprehensibility and clarity of questions.
In addition to covering the organisational levels
reflected in the qualitative interviews, the survey also
targeted pharmacists, lab coordinators and nurses
working in clinical trials in order to consider a variety
of perspectives and provide a bigger sample size. The
English-language survey was translated into French, in-
cluding back-translation and revision of terminologies.
Invitations to participate were sent via email and con-
tained the link to the English and French versions of
the survey. Data collection took place from August
2015 until January 2016. A total of 294 survey requests
were sent out by different organizations (Table 1) and
all contained the appeal to forward the survey to team
members.
In the introductory text, we informed respondents that
by filling in and pressing the “send” button they were
giving consent to participate in the survey. In addition,
respondents were assured of their anonymity and that it
would not be possible to link the answers to their email-
addresses. Respondents were informed that if they could
not give a general answer, they should answer the ques-
tion with reference to an on-going or most recent trial.
Categorical variables were described using absolute
and relative frequencies and percentages. Explorative
factor analysis (based on principal component analysis)Table 1 Survey distribution
Organisation distributing the survey
European and Developing Countries Clinical Trials Partnership (EDCTP)
Swiss Tropical and Public Health Institute
Two pharmaceutical companies
European Federation of Pharmaceutical Industries and Associations (EFPIA)with oblique rotation was performed on the survey
items to identify potential associations between the
protocol quality score (basing on different assessment
variables) and personal characteristics of the respon-
dents. The resulting factor scores were then regressed
on personal characteristics of the respondents. Inde-
pendent variables for the regression analyses were se-
lected based on prior knowledge and experience; other
potential covariates were screened but did not improve
the model. A p-value smaller than 0.05 was considered
statistically significant. Data were analysed using the




Thirty-six clinical trial staff participated in the key in-
formant interviews (Table 2). Through open questions
about efficiency, challenges and quality in the conduct
of trials, protocol suitability emerged as a topic in the
first five interviews in Ghana. To follow up on this
topic, we added questions about protocol suitability to
the remaining eight interviews in Ghana (no more than
13 trial staff were available for interviews in the two
clinical research centres in Ghana). Qualitative research
is centred on flexibility and the exploratory approach of
the study enabled adjustments to follow up on an emer-
ging topic [29]. We asked the questions on protocol
suitability in clinical research centres in Burkina Faso
and Senegal, as well.
Findings
Protocol characteristics With high frequency, inter-
viewees reported that a suitable trial protocol has to be
clear to avoid methodological and procedural uncer-
tainties that leave room for interpretation. Trial staff
emphasized the importance of making protocols under-
standable for everyone on site, including less skilled
staff like field workers, and consistent to avoid ambigu-
ities and contradictions. A bit less frequently, inter-
viewees mentioned the need to make protocols easy to
implement, i.e. avoiding too many measurements at the
same time. In addition, a few interviewees claimed that
a logical flow was sometimes missing and called for
well-structured protocols.Number of trial staff in SSA receiving the survey by email
80 investigators who had previously coordinated an EDCTP grant
109 trial staff who worked on the RTS,S malaria vaccine trials in SSA
40 trial staff contacts from Swiss TPH
43 trial staff
22 trial staff
Table 2 Role and experience of interviewees
Ghana Burkina Faso Senegal
(n = 8) (n = 16) (n = 12)
Role in trial Investigators 2 8 6
(n = 16)
Study coordinators 4 3 3
(n = 10)
Clinicians 1 3 2
(n = 6)




0 to 1 year 0 1 1
2 to 4 years 2 5 2
5 to 7 years 1 0 1
More than 7 years 5 10 8
Study Phase Phase I (a or b) 2 10 2
Phase II 2 13 3
Phase III 6 13 6
Phase IV 5 9 3
Type of trial Drug trial 4 16 9
Vaccine trial 7 13 7
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ing an approved ability to understand and carry out
procedures. Others favoured short protocols to facili-
tate work, without providing too many details that
would only lead to amendments and non-adherence
to protocol procedures. If protocols are too long,
staff only read the section relevant to the work they
have to execute.
“A long document to read can cause a problem.
Ideally, summarised protocols that get to the
essential points could be better for both the
researcher and the ethics committee. This
facilitates understanding and implementation
on the ground. So that's important.”
— Study coordinator, male, Burkina Faso, centre two
Interviewees from French-speaking countries stated
the need to translate the protocol into French, as tech-
nical staff are unlikely to understand English. Accord-
ing to interviewees, protocol translations were often of
bad quality, leading to errors and ambiguities.
Importance of context adaptation The importance of
context adaptation came up in half of the interviews,
independent of country and organisational level. One
third of participants reported recently working with
protocols that were not fully adapted to the setting.“I would tell you to try to really adapt to the realities
of the countries. If you give us a typical European
protocol that has to be reproduced here, I think we
are going to have problems. We do not have the same
manner of working. We do not have the same tools to
work with. So it might be important to really see
what is feasible in the country (…) If not, you will
have many, many deviations afterwards, because we
were not able to do that.”
— Study coordinator, female, Burkina Faso, centre two
Interviewees gave various examples of missing context
adaptation. First, their biggest concern was the needs of
trial participants, which protocols sometimes failed to
consider. Protocols should seek to burden trial partici-
pants as little as possible. For example, interviewees in
all three countries asserted that trial participants felt un-
comfortable with blood drawings; one Senegalese inves-
tigator said participants would rather accept four small
tubes instead of one big tube hence, it is important to
ensure that trials are as non-invasive as possible and to
discuss limitations in advance. Another example referred
to the heavy agricultural workload of local populations
during the rainy season; many trials deliberately take
place in this season due to high disease prevalence of
malaria, for example. Thus, trial procedures should
adapt to the time constraints of its participants. Second,
interviewees found that socio-cultural norms and values
were sometimes not respected in the protocol. Inter-
viewees gave various examples of this, like asking trial
participants about death or sexuality, which are taboo
subjects in these settings. A few interviewees mentioned
that trial participants would not answer these questions
honestly. Other examples included performing HIV tests
or pregnancy tests on minors or asking the name of neo-
nates when neonates are not given names in their first
seven days of life. One interviewee stressed the import-
ance of having a male and a female area for clinical trials
in Muslim environments. Interviewees believed that
better adaptation to possibilities and attitudes of trial
participants would also improve participants’ adherence
to trial protocols and decrease losses to follow-up.
Third, a few interviewees reported poor or no adapta-
tion to local capacities, systems and/or the structure of
the national health system. Staff experiences revealed
that certain laboratory tests or the amount of workforce
or expertise (e.g. presence of a psychologist) may not
be available on site but were required by the protocol.
A few interviewees claimed that the protocol timelines
given for patient flow were written for ideal settings
and circumstances, but not achievable in practice. Re-
spondents were aware that full adaptation to the site
was not possible for multicentre trials. However, they
reported that for certain multicentre trials, they were
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ting, such as adapting the formulation of questions,
which increased protocol suitability.
According to interviewees, protocols were not adapted
to local realities because the ones who elaborated the
protocol did not know the context. Hence, some proce-
dures in the protocols were difficult to put into practice.
Interviewee experiences revealed that it was best to adapt
the protocol to the setting in the development phase, as it
is far more challenging to adapt a finalized protocol.
Ideas for improving protocol suitability Across coun-
tries and positions, interviewees’ strongest suggestion for
increasing protocol suitability was to involve trial-site
staff in the protocol development phase. This idea was
raised by the majority of interviewees, often in an emo-
tional manner.
“So I think that involving the researcher in writing the
protocol allows one to avoid challenges in the field.
Because it is him [the researcher] who knows his
setting well.”
—Investigator, male, Burkina Faso, centre one
Interviewees had different suggestions on how best to
involve the trial team in protocol development. A few
participants proposed holding discussions with relevant
stakeholders prior to writing the protocol, while others
suggested writing the protocol together with the spon-
sor. A few recommended asking clinical trial staff to
review the first draft of the protocol, with the aim of
checking trial feasibility and providing added feedback.
A few others preferred to wait until the protocol was fi-
nalized and then discuss the implementation of the trial
in practice with the sponsor. For all trial staff, the object-
ive of their involvement would be to ensure that the trial
respected the realities of the setting and centre. Add-
itionally, a few mentioned that their input regarding
recruitment was of particular importance and would
potentially accelerate recruitment rates.
At the time of the interviews, half of the interviewed
trial staff was not involved in protocol development. Of
the other half, most were involved only insofar as they
received a draft protocol and corrected for coherency
and applicability.
“There have been protocol meetings on many studies,
but it is not all the studies that you get the opportunity
to be part of the protocol development and you find
out that in instances when you are not part of which
and where, you know a training did not trickle down
well to the end-users, myself included, there may be
errors caused.”
— Study coordinator, male, Ghana, centre oneOne Burkinabe investigator stated that participation in
protocol development depended on the sponsor: if it was
a pharmaceutical company, trial staff were not involved; if
it was a university, the sponsor and the site staff developed
the protocol together. A few Senegalese staff reported that
only recently, they were asked to provide inputs before a
protocol was finalized and submitted for ethical review.
Most of the principle investigators (PIs) interviewed were
allowed to give inputs during protocol development. One
interviewee shared his opinion that these PIs should solicit
input from the team.
“One the PIs should have it [the protocol]. And the PI
also has the responsibility of sub-delegate (…) if you
were the PI, it doesn’t necessarily mean you are the
technical person in some of the areas. So it is not
enough for the PI to just look at it and say ‘oh the
science is ok’, you need the technical people to look at
it and then they advise ‘ok this way’.”
— Quality assurance professional, male, Ghana
centre one
The majority of trial staff agreed that not only the PI
but also technical staff, like statisticians, data managers
and trial nurses, should be involved in protocol devel-
opment to prevent trial designs or data collection ap-
proaches which are difficult to implement. Others
expressed the following sentiment:
“When we work with a pharmaceutical company, it's
difficult to get everyone involved. But at least the PI
may be involved.”
— Investigator, male, Burkina Faso, centre two
Trial staff cited additional benefits of their involvement
to trial efficiency. According to interviewees, their involve-
ment would decrease the number of amendments, help to
find redundancies in the trial processes and improve the
preparation of staff for the trial. They were dissatisfied
with only executing protocols and claimed that collabor-
ation was missing. Trial staff was also of the opinion that
staff motivation would increase if they were allowed more
influence on the protocol.
Finally, two interviewees mentioned that protocols should
be written by investigators and sponsors together, so that
the investigators could learn protocol writing skills.
“When the monitors come for the training, we go
through documents and we say when such things in
our setting cannot be done like that. Then we have to
go back again. This is what I have criticized sometimes.
We must amend, go back, start again. Because if you
amend, we have to resubmit and so on. Whereas, if
maybe we could tolerate that for some studies, you can
Table 3 Role and experience of survey participants
Number of participants, n (%)
Recent primary role in clinical research




Quality assurance professional 7 (6.4)
Study coordinator 22 (20.0)
Pharmacist 3 (2.7)
Lab coordinator 7 (6.4)








Experience in clinical research
0 to 1 year 4 (3.6)
2 to 4 years 20 (18.2)
5 to 7 years 32 (29.1)
More than 7 years 54 (49.1)
Experience in drug trials 91 (82.7)
Experience in vaccine trials 63 (57.3)
Sponsor
Pharma companies 40 (36.4)
Other than pharma companies 29 (26.4)
Mixed 40 (36.4)
I do not know 1 (0.9)
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process is done together with the site. This will allow one
to take into account many aspects and once we start the
process, we won’t need to go backwards anymore.”
— Quality assurance professional, male, Burkina Faso,
centre two
Other ideas for increasing protocol suitability were
also presented with some frequency. One such idea in-
cluded conducting a test run with a dummy participant
to identify and tackle difficulties in advance, coordinate
activities and ensure that everyone knows their responsi-
bility before recruitment starts.
“Then we realized that the test run was our secret.
That was our success because we had virtually
identified all the possible problems, looked at how
they could be resolved before the real test.”
— Quality assurance professional, male, Ghana,
centre two
A few interviewees suggested including trial partici-
pants’ perspectives in the protocol development, as patient
challenges occur very frequently, e.g. during informed
consent and follow-up. Involving trial participants in dis-
cussions and knowing their perspectives would help to in-
crease protocol adherence, according to interviewees.
Having “lessons learned” meetings after trial completion
and providing sponsors with information about what went
wrong was also deemed to have a positive influence on fu-
ture trials. According to interviewees, identifying weak
spots and finding solutions prior to writing the next
protocol would avoid repeating the same mistakes and
allow staff to profit from experience.
Quantitative results
Participants
The final survey sample size was 110. Eleven records
were excluded because these respondents indicated a
country outside SSA as their main work place. Charac-
teristics of the respondents are presented in Table 3.
There were high proportions of PIs (26.4%) and trial
staff with more than seven years of clinical research ex-
perience (49.1%). The majority of respondents worked in
clinical research centres (71.8%) and 53.2% spent more
than 75% of their working time on clinical trials. The
distribution of survey participants across countries
(Table 4) reflected the number of clinical trials con-
ducted in different countries [30]. Only Malawi,
Zimbabwe and Nigeria were underrepresented in our
survey. We asked survey participants to forward the sur-
vey to colleagues working in clinical research, thus the
total number of surveys distributed is unknown and we
cannot calculate a response rate.Findings
Characteristics and context-adaptation of protocols
Protocol characteristics are presented in Table 5. Only
one third (38.2%) of all respondents considered proto-
cols as being easy to implement. About half of the sur-
vey participants rated trial protocols as being completely
understandable, clear and consistent.
Of the respondents, 65.1% considered the follow-up
procedure described in the trial protocol to be well
adapted to the setting, while 58.7% considered the inclu-
sion and exclusion criteria to be well adapted (Table 6).
Only about one third rated workforce availability
(30.9%), daily clinical practice (32.1%) and available in-
frastructure (35.8%) as well adapted to the protocol re-
quirements; thus, these elements were rated as having
the lowest degree of context-adaptation. Some 13.6%
considered participant incentives and 10% considered
Table 4 Distribution of survey participants per country
Country Number of participants, n (%)
Kenya 23 (20.9)
















Several countries in SSA 7 (6.4)
Total 110 (100)
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adapted to the context. By analysing the data from
English and French-speaking countries individually we
identified that trial staff in French-speaking countries
rated the level of adaptation to the setting of the in-
formed consent procedures, inclusion and exclusion
criteria, incentives, medical procedures, safety reporting
and follow-up as lower compared to staff from English-
speaking countries. In turn, staff from English-speaking
countries rated the level of adaptation to the setting of
availability and needs of trial participants, daily clinical
practice as well as workforce and infrastructure avail-
able as lower compared to staff from French-speaking
countries (no details given). However, it has to be con-
sidered that only 25 trial staff from French-speaking
countries participated in the survey.Table 5 Protocol characteristics
Protocol characteristics not at all [%] partially [%
Understandable (for all staff levels) 3.6 43.6
Easy to implement 6.4 53.6
Clear (no uncertainties) 7.3 39.1
Well structured 1.8 22.7
Complex 15.5 50.9
Consistent (e.g. no ambiguities) 4.6 39.1
Well translated 6.4 21.8The majority of respondents (56%) mentioned that
protocols were amended an average of three to five
times per trial; 7.3% mentioned more than five protocol
amendments per trial.
Measures to increase protocol suitability When asked
what measures would increase protocol suitability, in-
volvement of local staff in the study planning and proto-
col development was rated as the most helpful option by
respondents (61.8%) (Fig. 1).
This result was consistent across countries and posi-
tions. A related frequently selected approach to increase
protocol suitability was to have committees of investiga-
tors in multicentre trials (42.7%), consisting of investiga-
tors from all participating sites. On average, respondents
were more frequently working on multicentre trials than
on single centre trials (77% spent at least 50% of their
work time in multicentre trials). The second most help-
ful option mentioned was careful assessment of local
context, capacity and culture by sponsors (49.1%). How-
ever, the adaptation of the protocol to site and health
care specific systems in a single centre trial (11.8%) was
only rarely selected. Overall almost half (47.3%) rated
ensuring that everybody understands the protocol and
knows his/her role and responsibility in the trial as one
of the most helpful options, while the more concrete
measures of having a kick-off meeting or a dry run were
less frequently chosen (30.9 and 27.3%). Almost half
(41.3%) reported to have had a kick-off meeting for all of
their trials. Dry runs were less frequently implemented;
24.8% never had dry runs in any trial and 21.1% had dry
runs in all trials. Soliciting feedback from the site on
what went wrong in previous trials by sponsors was an-
other popular option for respondents (42.7%) to increase
protocol suitability. However, 40.4% had never had any
“lessons learnt meetings”. Only 1.8% considered that the
use of the open source protocol development technique
would increase protocol suitability, but 73.4% had never
heard of this technique.
Respondents were asked to tick the three options they
considered most helpful for increasing protocol suit-








Table 6 Adaptation of protocol procedures and in-protocol required resources to the setting
marginally adapted [%] partially adapted [%] well adapted [%] no opinion [%]
Informed consent procedure 3.6 39.1 56.4 0.9
Inclusion and exclusion criteria 3.7 36.7 58.7 0.9
Participant incentives for participation 13.6 45.5 36.4 4.6
Recruitment procedure 3.6 46.4 50.0 -
Data and information to be collected 4.6 36.7 57.8 0.9
Medical interventions 8.2 35.5 52.7 3.6
Medical procedures and decisions 7.3 39.5 51.4 1.8
Safety reporting and management 4.6 39.1 54.6 1.8
Follow-up procedure 2.8 30.3 65.1 1.8
Amount of workforce available 13.6 53.6 30.9 1.8
Infrastructure available 13.8 48.6 35.8 1.8
Availability and needs of trial participants 10.0 50.9 38.2 0.9
Daily clinical practice 8.3 56.9 32.1 2.8
Ethics committee system 8.2 46.4 44.6 0.9
Drug regulatory authority system 9.1 42.7 45.5 2.7
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from those that chose more than three options were
compared with the answers of respondents who cor-
rectly filled in the survey; the ones that chose more
than three options ranked checklist for practical steps,
assessment of setting, inclusion of trial participants’
perspective and adaptation to site as slightly higher.
However, including the ones that chose more than
three options did not change the measures’ ranking
order and, due to the small sample size, we included all
answers in the final results and figures.
The qualitative interviews suggested that trial teams
would consider their involvement in protocol develop-
ment as highly important. Figure 2 shows that one
quarter (26.4%) of trialists were not involved in proto-
col development at all; most were clinicians or study













































































































Fig. 1 Measures to increase protocol suitabilityReviewing the protocol was the most frequent manner
of involvement (47.3%).
Almost half (45.5%) indicated that it would be most
helpful if they were heavily involved (major involve-
ment) in protocol writing. However, as shown in Fig. 3;
the majority considered reviewing protocols and par-
ticipating in pre-discussions of protocols (both 66.4%)
as optimal.
Factor analysis of the different assessment variables
was performed to assess potential associations between
protocol quality and personal characteristics. The third
factor score was most strongly related to personal char-
acteristics of the study participants and described the
degree of implementability, understandability, clarity
and structure of the trial protocol. The only statistically
significant association found was the professional role










































































































































Fig. 3 Most helpful involvement of site staff
Vischer et al. Global Health Research and Policy  (2017) 2:11 Page 10 of 15roles, the third factor score was on average significantly
higher for PIs (difference = 0.43, 95%-confidence inter-
val = 0.04 to 0.83, p = 0.033) and significantly lower for
sponsor-investigators (difference = −1.10, 95%-confidence
interval = −1.85 to −0.35, p = 0.005) and quality assur-
ance professionals (difference = −1.22, 95%-confidence
interval = −2.02 to −0.42, p = 0.003).
Discussion
This study identified perceived deficits of protocol suit-
ability and yielded several measures to enhance protocol
suitability, as put forward by trial staff. According to trial
staff, protocol suitability constraints included ambiguity,
complexity and poor understandability for all staff levels.
Staff mentioned lack of clarity in procedural descriptions
and imprecise wording in protocols. Only one third of
the survey respondents rated protocols as easy to imple-
ment. While context adaptation was a main theme in
the qualitative interviews, survey respondents rated most
trial aspects as rather well adapted, particularly inclusion
and exclusion criteria and follow-up procedures. This
finding surprised us and is inconsistent with the litera-
ture, which cites follow-up as a challenge [31–33]. The
differences in the findings might be explained by the dif-
ferent methodologies used as literature findings base on
authors’ personal reflections. In turn, respondents cited
poor context adaptation of the protocol to the availabil-
ity and needs of trial participants as a constraint. The
importance of adapting projects to research participants’
cultural norms and values has been described elsewhere
[1, 33, 34]. Staff perceived protocols as being too rigid
for their settings. An example that was mentioned fre-
quently in interviews was the importance of minimising
blood draws. Trial participants in SSA are commonly
scared of giving blood as blood is considered sacred,
blood sampling is thought to make children ill and
there are local rumours surrounding “blood stealing”
and “blood selling” [1, 35, 36].According to trial staff, visit windows and patient
flow should also consider trial participants’ obligations,
e.g. that harvesting takes place at the end of the rainy
season. The lack of protocol adaptation to available site
workforce and to daily clinical practice, of particular
importance in hospital settings where trial activities are
added to routine care, indicates that the work burden
of trial implementation was underestimated by protocol
developers.
The literature also stresses the importance of context
adaptation for easy translation of protocol procedures
into practice [37, 38]. Alsumidaie states that, “The spon-
sors design clinical trials expecting them to fit into study
site operational infrastructures which leads to challenges
like study procedures that are incompatible with how
study sites operate” [39].
Context adaptation is more challenging in multicentre
trials, as procedures must be uniform across sites to en-
able the required pooled data analysis. However, Thoma-
son et al. state that standardisation of procedures across
all sites within a trial in SSA is not always possible due to
the differences in resources [33]. We argue that, for multi-
centre trials, the degree of adaptation to the context has
to be considered carefully to avoid protocols that are
overly site specific but that consider the cultural, social,
economic and political differences between the sites in-
volved. We suggest identifying commonalities among the
sites involved and accounting for differing socio-cultural
norms, but we acknowledge that this is difficult.
Measures to improve protocol suitability
Site staff identified a number of measures to improve
the suitability of protocols, described below (Fig. 4).
Involvement of site staff in protocol development
In both qualitative and quantitative results, local trial
staff involvement in developing the protocol came up
and was rated as the most helpful option for increasing
protocol suitability. The importance of site staff in-
volvement in trial planning has also been stressed in
the literature [11, 21, 32, 39]. Eastabrook et al. state,
“Given the important role of site staff for overall trial
success it is critical to understand their preferences and
experiences” [40], while Alsumidaie promotes trial site
involvement to create clinical trials that work oper-
ationally while reducing risks [39].
Half of the interviewees and three-quarters of survey
respondents (half of survey respondents were investiga-
tors) had been previously involved in protocol develop-
ment in some manner. It is important to carefully
choose the composition of the trial team involved in this
process. While key opinion leaders may give detailed sci-
entific input, they are often not the ones carrying out
the work on site. We agree with the respondents who
Fig. 4 Implementation of measures to increase protocol suitability
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particularly useful to increase suitability. Ideally, tech-
nical staff from various functional areas (investigator/
clinician, study coordinator, pharmacist, lab coordinator
and data manager) should be involved, though this
might not be possible for all sites in a multicentre trial.
A popular option to increase protocol suitability for
multicentre trials, as revealed in the survey, was to form
protocol writing committees consisting of one investiga-
tor from each site. Indeed, involving an operationally ex-
perienced investigator who solicits feedback from his/
her team and communicates the outcome to the sponsor
would lead to optimized protocols. Multicentre trials on
poverty-related diseases do not usually involve an exten-
sive number of trial sites, hence, it should be possible to
solicit feedback from all sites in the planning phase of
such trials. In cases where it is not possible to involve
one investigator from each site, at least the sites ex-
pected to have a high enrolment rate should be involved
in protocol development. Mbuagbaw et al. recommend
selecting national coordinators to participate in the con-
ception of multicentre trials [11]. The assistance of a
social scientist would also help to inform protocol devel-
opment by identifying context specificities. In line with
this, Cooper et al. also suggest the use of qualitative re-
search to identify the acceptability of the trial protocol
among other things [41]. The meningitis vaccine project
shares a positive experience of bringing trial teams to-
gether at meetings in the preparatory phase, which
empowered the team and fostered communication be-
tween sites [32]. In addition, this approach enabledplanners to anticipate and resolve operational issues and
minimize the number of protocol deviations.
Trial staff rated reviewing and pre-discussing the
protocol as the most helpful way to participate in
protocol development. This is in line with Alsumidaie,
who states that involvement is mainly about obtaining
feedback on how to better operate the study [39]. As
the sponsor is responsible for the research question and
scientific aspects of the protocol, the trial team could
provide valuable input in terms of protocol clarity,
implementability and adaptation to trial participant
needs. The latter is in line with literature stating that
staff input would be particularly important for recruit-
ment and follow-up of trial participants [32] as well as
feasibility of scheduled study visits [42]. We consider it
essential, that the site, in turn, is transparent and realis-
tic in terms of their capacities.
In addition to increasing protocol suitability, trial
staff mentioned several additional advantages of being
involved in the protocol preparation process. First, de-
veloping an appropriate protocol is a discipline that re-
quires training [31] and, according to interviewees and
the literature, involving local trial staff in this process
builds capacity and confidence [31, 43]. As there are
only a small number of locally initiated trials [44] and
limited career perspectives in clinical research [1, 45],
this is a crucial skill for investigators to acquire. Sec-
ond, staff saw being involved in protocol development
as a way of improving their preparedness for the trial.
Third, having an influence on the project would in-
crease trial staff ’s motivation, as opposed to having a
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approach, a participatory approach fosters ownership of
the trial [38, 43] and is also recommended by the trans-
boundary research principles of the Commission for
Research Partnerships with Developing Countries (KFPE)
[46]. Experiences from the meningitis vaccine project
also show that working closely with study staff can be
empowering, strengthen team spirit, boost staff motiv-
ation and increase everyone’s commitment [32]. Fourth,
it has been stated that mobilising collective intelligence
of various people for research protocols is a great bene-
fit for research [47].
Assessment of the context and setting
More careful assessment of the local context, capacity,
and culture by the sponsor was rated as the second
most helpful measure to increase protocol suitability.
Experiences from a trial in the Gambia are in line with
this; the authors state that baseline situation assess-
ments are required as each trial and site is unique [48].
For this purpose site assessments and pre-study-visits
are commonly performed by sponsors or contract re-
search organizations. While it is common practice to
use standard templates (checklists), information col-
lected this way is of limited value since they are fre-
quently focusing on issues influencing trial feasibility.
Instead, the questions should be tailored to the trial
and the setting, i.e. to the suitability. This includes, for
example, a more thorough assessment of the socio-
cultural context, local laws and customs where the trial
will be conducted and identification of risks and needs
upfront. This is in line with current trends toward
risk-based approaches, including risk assessments in
clinical development [49].
Our data suggest improvement of both, feasibility
and suitability assessments with a focus on workforce,
infrastructure (e.g. equipment) available and on avail-
ability of trial participants, respectively. Some estab-
lished clinical research centres in SSA have community
advisory boards (CABs) for community engagement
and to inform the community appropriately about the
study [50]. In view of our findings, it might be helpful
to involve the CAB at the conception stage of a trial, to
allow for socio-cultural adaptation. Additionally, we found
that engaging key staff from different organizational
levels during the visits was beneficial. It is important to
allocate enough time for such visits and ensure that they
are conducted at an early project stage, where changes
can still be incorporated. Moreover, it is important that
the monitors performing these visits are well qualified,
having both the requisite therapeutic knowledge and
cultural sensitivity on top of the generally required
knowledge of processes, protocols, regulations, labora-
tories and experience in clinical research.The two measures “involvement of site staff in proto-
col development” and “assessment of context and
setting” are not only increasing suitability but also
feasibility. However, these measures go beyond feasibil-
ity through enabling effective and efficient execution of
the trial and considering settings and cultures by fol-
lowing the protocol.
Good understanding of trial protocols
Making sure that everyone understands the protocol and
knows his/her role and responsibility in the trial is an
important factor, as put forward by trial staff and the
literature [51]. However, it is challenging in practice, as
often staff in SSA, particularly in trials on neglected
diseases, have neither a medical background nor prior
experience in clinical research [10]. A survey on site
initiation visits confirmed our findings, as protocol spe-
cific training emerged as a main request by trial staff
[40]. The initiation visit presents an ideal opportunity
for the site staff to go through each trial procedure in
detail and discuss the operationalization of the protocol
with the monitor. To coach the team, ensure compli-
ance with the trial protocol and help to correct prac-
tices, ideally, the monitor should remain on site during
the first few days of recruitment or re-visit the site
shortly after recruitment has started. Similarly, Tinto
et al. suggested that the Good Clinical Practice trainer
supports the trial team in resource-limited settings during
trial start [52].
Advantages of prospective planning
We are aware that the suggestions presented here to in-
crease protocol suitability involve costs and might cause
study start delays. However, a recent study by CTTI
(Clinical Trials Transformation Initiative) confirmed that
to overcome inefficiencies, an approach that emphasizes
error prevention over remediation should be the norm
[21]. Currently, the intense monitoring, auditing and
inspecting processes test for errors during the trial
rather than prospectively identifying, preventing and
correcting them. In their quality by design project, the
CTTI authors suggest, in line with our findings, that
protocol issues should be identified early to minimize
their impact and to describe the infrastructure, resources
and training needs of the site [53]. Another study
showed that to ensure data integrity, training and motiv-
ating sites is much more cost-effective compared to
100% source data verification [54]. To ensure quality,
CTTI encourages critical thinking, addressing imple-
mentation challenges proactively and incorporating les-
sons learned into other trials as a means of continuous
improvement. Protocol suitability-enhancing measures
may also reduce the number of amendments, minimiz-
ing its negative impact on costs, duration, and quality of
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survey respondents indicated three to five amendments,
on average, per protocol.
Despite the intense pressure on sponsors to accelerate
drug development [8], realistic timelines and sufficient
time for trial preparation is important for implementing
protocol suitability enhancing measures. This is in line
with CTTI’s assertion that, “Rewarding trial teams who
minimize the time to first patient enrolled may serve as
a disincentive to devoting time to identifying and pre-
venting errors that matter through trial design” [42].
To ensure that site staff involvement does not delay
protocol development and that the process is as efficient
as possible, it is important that one person leads the
process on the sponsor side and that the protocol devel-
opment process is clearly defined. The global health
trials webpage offers a concept protocol template that
provides a format for recording discussions and for pre-
senting a protocol to stakeholders at an early stage [19].
Another promising tool for cost-effective and efficient
involvement of stakeholders in protocol development is
SWOG, a web-based protocol writing system with inte-
grated support for collaborative reviewing and editing
[55]. This tool enables sponsors and trial teams to see
each other’s comments and reactions immediately, des-
pite the geographical separation, which is particularly
large for clinical trials in SSA [18]. The objective of the
software developer was to increase the natural collabora-
tive protocol writing process and facilitate interactions
and communications among protocol writers [55].
Internal validity
Due to time restrictions in this investigation, we covered
the site teams’ perspective without incorporating the
sponsors’ view. The interviewer of the qualitative inter-
views is a female Swiss scientist, which may have biased
interviewees towards giving a positive answer. The survey
sample is a convenience sample, as it is impossible to
eliminate nonresponse bias in online surveys. However,
triangulation of perspectives through mixed methods ap-
proach strengthened our findings. As EDCTP, pharma-
ceutical companies and Swiss TPH sent out the survey
and are simultaneously potential sponsors or funders,
survey respondents might have had a tendency to an-
swer questions in a manner that would be viewed
favourably by these organisations. However, we tried to
mitigate this concern by ensuring anonymity in the sur-
vey’s introductory text. Another limitation was incom-
plete responses received for a few questions. Lastly, we
acknowledge that according to the sample size calcula-
tion, 200 survey answers would have been required, but
despite many efforts we only received 110 answers. Pos-
sible reasons were poor internet connectivity and time
constraints of trial staff. However, one should considerthat the total number of clinical research staff working
in SSA is likewise relatively small and we believe that
our results are representative for established clinical re-
search centres in SSA.
External validity
We speculate that many of our findings are also applic-
able for Northern settings. Due to the lack of literature
on the topic in general and particularly in SSA, the ma-
jority of literature cited in this manuscript is based on
the Northern setting and is mostly in line with our find-
ings. An example that is equally true for Northern and
Southern settings is the practice of sponsors designing
clinical trials, expecting them to fit to the trial site [39].
Based on trial experiences in Northern settings, Farrell
et al. recommend that differing clinical practices, work-
ing environments, and governance regulations should be
taken into account [38] and CTTI recommends involv-
ing different levels of site staff to increase the quality of
the trial [56].
To the best of our knowledge, this is the first study on
trial protocol suitability for clinical trials in SSA. We en-
courage further research on trial protocols and their
non-scientific parts, in particular. We promote the ex-
ploratory mixed methods methodology in the context
where little is known about the research topic, as this
approach allows new and important themes to emerge
and provides the flexibility to adapt to these themes in
subsequent steps.
Conclusions
By applying an exploratory mixed methods approach, we
identified a lack of clarity, implementability and adapta-
tion to trial participants, workforce and infrastructure as
the main constraints of protocol suitability. We found
that site staff involvement in protocol development,
careful assessment of local context, capacity and culture
as well as ensuring that staff understands the protocol
are the most helpful measures towards increasing
protocol suitability, according to trial teams. Including
technical aspects into such preparations and site in-
volvement would simultaneously also enhance the feasi-
bility of trials in the reviewed context. Considering and
involving the site’s input at an early stage of protocol
development was deemed the best way to increase
involvement, as the majority of trial staff did not seek
major involvement in protocol development. Our data
suggests that the measures presented increase imple-
mentability, efficiency and quality of trials in the long
run, although it might slightly prolong the protocol
development phase. We consider such an approach as
particularly useful for clinical trials in SSA, as the pro-
tocols are mostly developed by Northern sponsors who
might not be familiar with the setting.
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